Zero ARIA-E in early Alzheimer's sets PMN310 apart — Phase 1b top-line data will show whether the biomarker signals translate to efficacy

ProMIS Neurosciences is a clinical-stage biopharmaceutical company developing a treatment for early Alzheimer's disease that is not yet approved.

PMN310's blinded six-month interim from 136 AD patients showed zero ARIA-E across all genotypes, including APOE4 homozygotes, separating it from the safety liability that shadows approved anti-amyloid antibodies. Whether that safety advantage matters commercially depends entirely on Phase 1b top-line data showing clinical benefit, as biomarker trends (pTau217 and MTBR-tau243 declines) are consistent with target engagement but not efficacy proof. Cash of $53M covering through 2027 clears the readout hurdle, but PMN310 is a Phase 1b antibody in a field where lecanemab and donanemab have already set a high clinical bar.